Thrombolytic treatment for myocardial infarction: An examination of practice in 39 United Kingdom hospitals

Heart

Volumn 78, Issue 1, 1997, Pages 28-33

  Birkhead, J S ^a  

^a NORTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

Audit; Myocardial infarction; Thrombolytic treatment

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MEDICAL PRACTICE; PRIORITY JOURNAL; ST SEGMENT ELEVATION; UNITED KINGDOM;

EID: 0030740686     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.78.1.28     Document Type: Article

References (18)

1. GISSI (Gruppo Italiano per lo Studio della Streptochinesi nell'Infarto miocardico). Effectivness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;i:397-401.
2. ISAM (Intravenous Streptokinase in Acute myocardial Infarction) Study Group. A prospective study of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med 1986;314:1465-71.
3. AIMS (APSAC Intervention Mortality Study) Trial study group. Effects of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;i:545-9.
4. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;ii:349-60.
5. ISIS-3: a randomised comparison of streptokinase v tissue plasminogen activator v anistreplase and of aspirin plus heparin v aspirin alone among 41229 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992;339:753-70.
6. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995;345:669-82.
7. GISSI-2: a factorial randomised trial of alteplase versus steptokinase and heparin versus no heparin among 12490 patients with acute myocardial infarction. Lancet 1990; 336:65-71.
8. Ketley D, Woods KL. Impact of clinical trials on clinical practice: example of thrombolysis for acute myocardial infarction. Lancet 1993;342:891-4.
9. Birkhead JS on behalf of a Joint Audit Committee of the British Cardiac Society and the Cardiology Committee of the Royal College of Physicians of London. Time delays in provision of thrombolytic therapy in six district hospitals. BMJ 1992;305:445-8.
10. Rogers WJ, Bowlby LJ, Chandra NC, French WJ, Gore JM, Lambrew CT, et al. Treatment of myocardial infarction in the United States (1990 to 1993). Circulation 1994;890:2103-14.
11. Phillips BG, Yim JM, Brown EJ, Bittar N, Hoon TJ, Celestin C, et al. Pharmacologic profile of survivors of acute myocardial infarction at United States academic hospitals. Am Heart J 1996;131:872-7.
12. French JK, Williams BF, Hart HH, Wyatt S, Poole JE, Ingram C, et al. Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ 1996;312:1637-41.
13. Adams J, Trent R, Rawles J, on behalf of the GREAT group. Earliest electrocardiographic evidence of myocardial infarction: implications for thrombolytic treatment. BMJ 1993;307:409-12.
14. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343:311-22.
15. Hai Shiang Lee, Cross SJ, Rawles JM, Jennings KP. Patients with suspected myocardial infarction who present with ST depression. Lancet 1993;342:1204-7.
16. LATE Study Group. Late assessment of thrombolytic efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342:759-66.
17. Aronow WS. Prevalence of presenting symptoms of recognised acute myocardial infarction and unrecognised healed myocardial infarction in elderly patients. Am J Cardiol 1987;60:1182.
18. Karlson BW, Herlitz J, Hartford M. Prognosis in myocardial infarction in relation to gender. Am Heart J 1994; 128:477-83.